{
    "nct_id": "NCT04105010",
    "official_title": "A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)",
    "inclusion_criteria": "1. Obtained written informed consent\n2. Patients must have histologically confirmed peripheral T-cell lymphoma according to the 2016 revision of the World Health Organization classiﬁcation of lymphoid neoplasms. Tumor samples are required for central pathology review to confirm the diagnosis.\n3. Patients must have measurable disease according to the Lugano criteria.\n4. Patients should be transplant-ineligible upon their entry into this study, and must have relapsed after or been refractory/intolerant to ≥ 1 (but not > 3) prior systemic therapy(ies) for PTCL.\n5. Adequate bone marrow reserve and organ system functions.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Any unsolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 from previous anti-cancer therapy (except alopecia).\n2. Active infections, active or latent tuberculosis.\n3. Patients with severely decreased lung function.\n4. History of heart failure or QT interval prolongation.\n5. Central nervous system (CNS) or leptomeningeal lymphoma.\n6. History of treatment with Janus kinase (JAK) or signal transducer and activator of transcription 3 (STAT3) inhibitor.\n7. Patient has undergone an allogeneic stem cell transplant. Patient had autologous stem cell transplant within 6 months.",
    "miscellaneous_criteria": ""
}